Molecular Partners AG
c/o Department of Biochemistry
Winterthurerstrasse 190
Zürich
8057
Tel: 41-44-635-65-00
Fax: 41-44-635-65-07
Website: http://www.molecularpartners.com/
Email: info@molecularpartners.com
81 articles about Molecular Partners AG
-
Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
4/6/2021
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced that the first patient has been dosed in a Phase 2a clinical trial of ensovibep, a DARPin® therapeutic candidate designed to bind to the SARS-CoV-2 spike protein at three distinct locations to prevent viral entry into cells.
-
Molecular Partners Nominates Dominik Höchli, M.D., for Election to Its Board of Directors
3/25/2021
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the nomination of Dominik Höchli, M.D., to the Company's Board of Directors proposed for election at the 2021 Annual General Meeting on April 21, 2021.
-
Clinical Catch-Up: March 15-19
3/22/2021
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look. -
With more European countries pausing dosing of AstraZeneca’s COVID-19 vaccine over concerns about potential blood clotting side effects, Russia is seeking to fill in the gaps with its Sputnik V vaccine.
-
Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral Candidate, ensovibep, in NIH-Sponsored ACTIV-3 Trial
3/15/2021
ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021
-
Molecular Partners Nominates Agnete Fredriksen for Election to Its Board of Directors
3/11/2021
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the nomination of Agnete Fredriksen, Ph.D., to the Company's Board of Directors proposed for election at the 2021 Annual General Meeting on April 21, 2021.
-
Molecular Partners to Present Data from Localized Immune Agonist (MP0317), T-cell Engager, and Peptide-MHC Immunotherapy Programs at AACR Annual Meeting
3/10/2021
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the upcoming presentation of four posters with data supporting three of the company's immunotherapy programs at the American Academy for Cancer Research Virtual Annual Meeting running April 10-15, 2021.
-
Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers
3/9/2021
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, announced initial results from its ongoing phase 1 study of its first tri-specific COVID-19 antiviral treatment, ensovibep, in healthy volunteers.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
-
Molecular Partners Publishes Audited Financial Results for 2020 and Annual Report 2020
2/26/2021
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, published its audited Financial Results for 2020 and the company's 2020 Annual Report.
-
Molecular Partners to Present at Upcoming Healthcare Investor Conferences - Feb 22, 2021
2/22/2021
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or attend several upcoming virtual healthcare investor events in February and March 2021.
-
Molecular Partners Reports Corporate Highlights from Q4 2020 and Key Financials for FY2020
2/5/2021
Announced positive safety data from first dose cohort of ongoing phase 1 COVID-19 study which is on track to report data from all cohorts in Q1 2021
-
Molecular Partners and Novartis COVID-19 Antiviral Candidate, Ensovibep, Maintains Binding and Neutralization of New Viral Variants in vitro
2/3/2021
New study shows that Molecular Partners' tri-specific antiviral DARPin® candidates, ensovibep (MP0420) and the Company's preclinical candidate, MP0423, remain therapeutically active against the known mutations of SARS-CoV-2 including those present in the United Kingdom (UK) and South Africa (SA) variants
-
Molecular Partners to Present at Upcoming Healthcare Investor Conferences
1/6/2021
Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin; therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or attend several upcoming virtual healthcare investor events in January, 2021.
-
Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy
12/17/2020
First-in-human data from ongoing phase 1 study of MP0310 (AMG 506) demonstrate encouraging biological activity, including successful localized tumor engagement and saturation
-
Molecular Partners to Share Clinical Data and Expanding Portfolio Strategy at Virtual R&D Day on December 17, 2020
12/2/2020
New data from clinical and preclinical oncology programs to be presented Preliminary Phase 1 data from anti-COVID-19 candidate MP0420 (ensovibep) expected
-
Molecular Partners to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
11/30/2020
Molecular Partners AG announced that Dr. Patrick Amstutz, CEO of Molecular Partners, will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 3:55 - 4:25 PM Eastern Time.
-
Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin(R) Therapeutic Candidate MP0420
11/23/2020
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420, a DARPin® therapeutic candidate for the potential treatment and prevention of COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
-
Interim Management Statement Q3 2020 of Molecular Partners: Emergence of New Opportunities and Strong Platform Validation of DARPin® Therapeutics
10/29/2020
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced its interim management statement for the period ending September30, 2020.